|
LOC110806263
|
Malignant neoplasm of urinary bladder
|
0.100 |
GeneticVariation |
BEFREE |
The TERT promoter mutations were most frequently present in bladder cancer (68.6%), followed by central nervous system tumors (28.7%), thyroid cancer (15.4%), prostate cancer (9.3%), endometrial carcinoma (3.7%), rhabdomyosarcoma (1.4%), colorectal cancer (1%), epithelial ovarian carcinoma (0.7%) and breast cancer (0.7%).
|
31669704 |
2020 |
|
LOC110806263
|
Bladder Neoplasm
|
0.100 |
GeneticVariation |
BEFREE |
The TERT promoter mutations were most frequently present in bladder cancer (68.6%), followed by central nervous system tumors (28.7%), thyroid cancer (15.4%), prostate cancer (9.3%), endometrial carcinoma (3.7%), rhabdomyosarcoma (1.4%), colorectal cancer (1%), epithelial ovarian carcinoma (0.7%) and breast cancer (0.7%).
|
31669704 |
2020 |
|
LOC110806263
|
Malignant neoplasm of thyroid
|
0.100 |
GeneticVariation |
BEFREE |
The association between telomerase reverse transcriptase (TERT) promoter mutations and some clinical behaviors in thyroid cancer remains controversial and requires additional investigation.
|
31655978 |
2020 |
|
LOC110806263
|
Malignant neoplasm of thyroid
|
0.100 |
GeneticVariation |
BEFREE |
The TERT promoter mutations were most frequently present in bladder cancer (68.6%), followed by central nervous system tumors (28.7%), thyroid cancer (15.4%), prostate cancer (9.3%), endometrial carcinoma (3.7%), rhabdomyosarcoma (1.4%), colorectal cancer (1%), epithelial ovarian carcinoma (0.7%) and breast cancer (0.7%).
|
31669704 |
2020 |
|
LOC110806263
|
Carcinoma, Transitional Cell
|
0.100 |
Biomarker |
BEFREE |
TERT- beyond the territory: Usage of PCR-based TERT promoter assay in defining urothelial carcinoma in a case of long-standing prostatic adenocarcinoma.
|
31630874 |
2020 |
|
LOC110806263
|
Glioblastoma
|
0.100 |
GeneticVariation |
BEFREE |
Predicting TERT promoter mutation using MR images in patients with wild-type IDH1 glioblastoma.
|
30948344 |
2020 |
|
LOC110806263
|
melanoma
|
0.100 |
GeneticVariation |
BEFREE |
Although TERT promoter mutations have been associated with a worsened prognosis in melanoma, the relationship between mutation status and downstream telomerase activity and telomere length remains convoluted.
|
31425705 |
2020 |
|
LOC110806263
|
Neoplasm Metastasis
|
0.100 |
GeneticVariation |
BEFREE |
In FTC, TERT promoter mutations were significantly associated with age, distant metastases, advanced TNM stage, persistence/recurrence, and disease-specific mortality.
|
31655978 |
2020 |
|
LOC110806263
|
Neoplasms
|
0.100 |
GeneticVariation |
BEFREE |
Besides, our data support an association between TERT promoter mutations and histologically malignant features, suggesting a possible molecular role in stratifying patients into intermediate- to high-risk tumor.
|
31463729 |
2020 |
|
LOC110806263
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Selected cases were also subjected to whole-exome sequencing (WES; n = 4), RNA-sequencing (n = 6), Archer FusionPlex assay (n = 5), methylation profiling using the Illumina MethylationEPIC (850k) array platform (n = 6), and TERT promoter sequencing (n = 5).Six neoplasms occurred in females.
|
31383964 |
2020 |
|
LOC110806263
|
Neoplasms
|
0.100 |
GeneticVariation |
BEFREE |
In DTC and PTC, TERT promoter mutations were significantly associated with sex, age, tumor size, vascular invasion, extrathyroidal extension, lymph node and distant metastases, advanced tumor, nodes, and metastasis (TNM) stage, persistence/recurrence, and disease-specific mortality.
|
31655978 |
2020 |
|
LOC110806263
|
Thyroid Neoplasm
|
0.100 |
GeneticVariation |
BEFREE |
The association between telomerase reverse transcriptase (TERT) promoter mutations and some clinical behaviors in thyroid cancer remains controversial and requires additional investigation.
|
31655978 |
2020 |
|
LOC110806263
|
Thyroid Neoplasm
|
0.100 |
GeneticVariation |
BEFREE |
The TERT promoter mutations were most frequently present in bladder cancer (68.6%), followed by central nervous system tumors (28.7%), thyroid cancer (15.4%), prostate cancer (9.3%), endometrial carcinoma (3.7%), rhabdomyosarcoma (1.4%), colorectal cancer (1%), epithelial ovarian carcinoma (0.7%) and breast cancer (0.7%).
|
31669704 |
2020 |
|
LOC110806263
|
Adult Glioblastoma
|
0.100 |
GeneticVariation |
BEFREE |
Predicting TERT promoter mutation using MR images in patients with wild-type IDH1 glioblastoma.
|
30948344 |
2020 |
|
LOC110806263
|
Childhood Glioblastoma
|
0.100 |
GeneticVariation |
BEFREE |
Predicting TERT promoter mutation using MR images in patients with wild-type IDH1 glioblastoma.
|
30948344 |
2020 |
|
LOC110806263
|
Thyroid carcinoma
|
0.100 |
GeneticVariation |
BEFREE |
The TERT promoter mutations were most frequently present in bladder cancer (68.6%), followed by central nervous system tumors (28.7%), thyroid cancer (15.4%), prostate cancer (9.3%), endometrial carcinoma (3.7%), rhabdomyosarcoma (1.4%), colorectal cancer (1%), epithelial ovarian carcinoma (0.7%) and breast cancer (0.7%).
|
31669704 |
2020 |
|
LOC110806263
|
Thyroid carcinoma
|
0.100 |
GeneticVariation |
BEFREE |
Average frequencies of TERT promoter mutations in DTC, papillary (PTC), and follicular (FTC) thyroid carcinomas were 10.9%, 10.6%, and 15.1%, respectively.
|
31655978 |
2020 |
|
LOC110806263
|
Carcinoma of bladder
|
0.100 |
GeneticVariation |
BEFREE |
The TERT promoter mutations were most frequently present in bladder cancer (68.6%), followed by central nervous system tumors (28.7%), thyroid cancer (15.4%), prostate cancer (9.3%), endometrial carcinoma (3.7%), rhabdomyosarcoma (1.4%), colorectal cancer (1%), epithelial ovarian carcinoma (0.7%) and breast cancer (0.7%).
|
31669704 |
2020 |
|
LOC110806263
|
Differentiated Thyroid Gland Carcinoma
|
0.100 |
GeneticVariation |
BEFREE |
Association between TERT promoter mutations and clinical behaviors in differentiated thyroid carcinoma: a systematic review and meta-analysis.
|
31655978 |
2020 |
|
LOC110806263
|
Glioblastoma Multiforme
|
0.100 |
GeneticVariation |
BEFREE |
Predicting TERT promoter mutation using MR images in patients with wild-type IDH1 glioblastoma.
|
30948344 |
2020 |
|
LOC110806263
|
Urothelial Carcinoma
|
0.100 |
Biomarker |
BEFREE |
TERT- beyond the territory: Usage of PCR-based TERT promoter assay in defining urothelial carcinoma in a case of long-standing prostatic adenocarcinoma.
|
31630874 |
2020 |
|
LOC110806263
|
Secondary Neoplasm
|
0.100 |
GeneticVariation |
BEFREE |
In FTC, TERT promoter mutations were significantly associated with age, distant metastases, advanced TNM stage, persistence/recurrence, and disease-specific mortality.
|
31655978 |
2020 |
|
LOC110806263
|
Malignant neoplasm of urinary bladder
|
0.100 |
GeneticVariation |
BEFREE |
Combined genetic and epigenetic alterations of the TERT promoter affect clinical and biological behavior of bladder cancer.
|
30350309 |
2019 |
|
LOC110806263
|
Malignant neoplasm of urinary bladder
|
0.100 |
GeneticVariation |
BEFREE |
Samples were analyzed for TERT promoter mutations with Safe-SeqS, a sequencing error-reduction technology, and sequenced using a targeted panel of the 10 most commonly mutated genes in bladder cancer on the Illumina MiSeq platform.
|
30447301 |
2019 |
|
LOC110806263
|
Malignant neoplasm of urinary bladder
|
0.100 |
GeneticVariation |
BEFREE |
TERT promoter mutations occur in the majority of glioblastoma, bladder cancer (BC), and other malignancies while the ETS family transcription factors GABPA and its partner GABPB1 activate the mutant TERT promoter and telomerase in these tumors.
|
31802036 |
2019 |